Recent research have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopamine signaling. While GLP activators are widely employed for treating type 2 T2DM, their emerging effects on reward circuits, specifically influenced by dopamine networks, are gaining considerable interest. This report prov… Read More